Omeros Corp

Omeros Corp (OMRS) – Seattle‑based biotech developing orthopedics, rheumatology, urology and cardiovascular drugs. Despite a 23% year‑to‑date decline, it remains focused on innovation across 6 therapeutic areas.

Omeros Corp’s Yartemlea receives historic FDA approval for HSCT patients, positioning the company as a leader in transplant‑associated TA‑TMA therapy and boosting its revenue outlook.

Omeros’ stock jumps after FDA approval of YARTEMLEA®, the first therapy for transplant‑associated thrombotic microangiopathy – a rare, life‑threatening complication.

Omeros’ FDA approval of YARTEMLEA® turns a biotech risk‑maker into a revenue generator, driving a 100% share surge and unlocking high‑price specialty therapy opportunities.

Omeros Corp’s diversified pipeline—from orthopedics to pain management—offers a rare chance for upside amid pharma’s market turmoil, with investors watching key clinical milestones.

Omeros Corp, a Seattle-based biopharmaceutical company, is preparing to announce its second-quarter financial results on August 14, 2025, amidst market fluctuations and investor anticipation.

Omeros Corp, a biopharmaceutical company, is navigating financial challenges while continuing to focus on expanding its product pipeline and addressing unmet medical needs.

Omeros Corp is set to release its first-quarter financial results, with analysts expecting a slight improvement in earnings per share, but questions remain about the company’s ability to achieve sustainable profitability in a competitive industry.